Share Buyback

/**/

RNS Number : 3195N EKF Diagnostics Holdings PLC 31 December 2025  

    EKF Diagnostics Holdings plc ("EKF" or the "Company")   Share Buyback   EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 43,000 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 25.56 pence per share. The Ordinary Shares purchased will be held in treasury.   Aggregated information  

Date of purchase

30 December 2025

Number of Ordinary Shares purchased

43,000

Highest price paid per Ordinary Share

25.56p

Lowest price paid per Ordinary Share

25.56p

Volume weighted average price paid

25.56p

   Transaction details   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:  

Number of Ordinary Shares purchased

Transaction price (GBp)

Time of transaction

Trading venue

30,000

25.56p

15:31:59

AIMX

13,000

25.56p

16:40:39

AIMX

  Total voting rights   Following the purchase, the Company's total issued share capital will consist of 435,383,092 Ordinary Shares, of which 1,413,980 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 433,969,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.   PDMR dealing   As part of the buyback and within the above aggregate purchase, EKF acquired 13,000 Ordinary Shares in total at a price of 25.56 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). EKF acquired 4,333 and 8,667 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.   Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 127,970,000 Ordinary Shares.    Additional disclosures relating to this PDMR dealing are detailed below.     This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).      The person responsible for arranging the release of this Announcement on behalf of the Company is Julian Baines, Executive Chair.    

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Gavin Jones, Chief Executive Officer



  Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Patrick Weaver







Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654





   

  About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)   EKF is an AIM-listed global diagnostics business focussed on:  

●

Point-of-Care analysers in the key areas of Hematology and Diabetes 

●

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

  EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.   Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them  

1  

Details of the person discharging managerial responsibilities / person closely associated  

a)  

Name

Christopher Mills

2  

Reason for the notification  

a)  

Position/status  

Non-Executive Director

b)  

Initial notification /Amendment  

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

EKF Diagnostics Holdings plc

b)  

LEI  

213800DXTF3EAUK1AR05  

4  

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

a)  

Description of the financial instrument, type of instrument

Ordinary Shares of 1 pence each





Identification code

GB0031509804  





b)  

Nature of the transaction    

Disposal of Ordinary Shares

c)  

Price(s) and volume(s)











Price(s)

Volume(s)







25.56p

13,000











d)  

Aggregated information







- Aggregated volume

n/a





- Price







e)  

Date of the transaction    

  30 December 2025

f)  

Place of the transaction    

London Stock Exchange, AIMX







     

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  MSCFDDFSFEISELE